Onconova, Pangea team up to find biomarkers for cancer drug rigosertib

Mar. 23, 2023 8:51 AM ETOnconova Therapeutics, Inc. (ONTX)By: Ravikash, SA News Editor

Shot of a businessman and businesswoman shaking hands in a modern office

Delmaine Donson

  • Onconova Therapeutics (NASDAQ:ONTX) and Pangea Biomed are collaborating to identify biomarkers of response to Onconova's cancer drug candidate rigosertib.
  • The research partnership will use Pangea's proprietary algorithmic platform ENLIGHT to identify the biomarkers.
  • "By leveraging Pangea’s AI platform to identify predictive biomarkers of response to rigosertib, we aim to inform a precision medicine approach to selecting additional PLK1-dependent tumors and other indications for its potential evaluation," said Onconova's President and CEO Steven Fruchtman.
  • ONTX +1.11% to $0.72 premarket March 23

Recommended For You

Comments

To ensure this doesn’t happen in the future, please enable Javascript and cookies in your browser.
Is this happening to you frequently? Please report it on our feedback forum.
If you have an ad-blocker enabled you may be blocked from proceeding. Please disable your ad-blocker and refresh.